Diversity and Equity Are Critical to the Work We Do
Systemic racism is as real as any disease.
The biopharmaceutical industry is committed to driving real change and improving health outcomes for patients in underserved communities.
Our Commitment to Equity
Equity is critical to the health and well-being of Black and Brown communities, and it remains essential to a robust ecosystem of innovation. America’s biopharmaceutical companies are pushing for necessary systemic and long-term change to better meet the needs of Black and Brown America.
Our Continued Commitment to Industry Change
Health Equity
We’re working with patients, community groups and policymakers to address
social determinants of health and to drive proactive research that expands
data collection and improves health outcomes.
We’re committed to working toward a clinical trials infrastructure that addresses health disparities and closes the gap in clinical trial diversity to better reflect the intended treatment population.
Talent
We aim to grow the talent pool, create new pathways to our industry and foster more inclusive work environments so that our workforce better reflects census representation top to bottom and side to side.
Voices from Our Catalyst Blog
PhRMA published our commitment to racial equity and inclusion in the New York Times as well as in DC-based, Black-owned newspapers the Informer and the AfroAmerican. This public declaration is an important milestone for our industry as we continue to take concrete steps to address systemic racism and work towards a more equitable future…
When I first started at PhRMA two and a half years ago, our organization was just starting to talk about how we could increase and activate our commitment to diversity & inclusion (D&I). As senior director of talent acquisition, some of my first tasks were to build an inhouse recruiting team and develop a D&I strategy for the organization…
“Creating a trusted partnership between the biopharmaceutical industry and communities of color will not happen overnight. It will take a sustained commitment to establish meaningful relationships that move us from health disparity to health equity.
I urge you to follow the progress at PhRMA.org/Equity.”
A Message from PhRMA President and CEO Stephen J. Ubl
Reports and Agency Comments
Comments on CMS Request for Information (RFI) on Closing the Health Equity Gap in CMS Quality Programs
The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciate the opportunity to comment on proposed Medicare FY 2022 Inpatient Psychiatric Facilities Prospective Payment System and Quality Reporting Updates for Fiscal Year Beginning October 1, 2021. PhRMA's comments are specifically in response to the Request for Information on Closing the Health Equity Gap in CMS Quality Programs.
PhRMA Comments to OMB: Methods and Leading Practices for Advancing Equity and Support for Underserved Communities Through Government
The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to comment on the OMB's Request for Information (RFI), “Methods and Leading Practices for Advancing Equity and Support for Underserved Communities Through Government,” which was published in the Federal Register on May 5, 2021.
Medicines in Development for Health Equity 2021 Report
Today, there are more than 800 medicines in development for diseases that disproportionately affect racial and ethnic communities. A new report from PhRMA explores the medicines that target these diseases and conditions, which not only affect these racial and ethnic communities at a higher rate, but are also associated with worse COVID-19 outcomes.
PhRMA Comments to NIH Request for Information on Advancing and Strengthening Racial Equity in the Biomedical Research Workforce
The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to comment on the NIH’s request for information on approaches to advance racial equity, diversity, and inclusion within all facets of the biomedical research workforce and expand research to eliminate health disparities and foster equity.
